Director Pauls Matthew of Pelthos Therapeutics Inc. (NASDAQ: PTHS) completed the sale of 786 shares of the company's common stock on April 2, 2026, generating approximately $16,439 in proceeds.
The disposition occurred in two separate transactions. The first sale comprised 415 shares at a weighted average price of $20.5154, with execution prices spanning from $20.30 to $20.78. The second sale consisted of 371 shares at a weighted average price of $21.3628, with trade prices ranging from $21.31 to $22.03.
Following these transactions, Matthew's direct stake in Pelthos stands at 15,150 shares. The sales were carried out pursuant to a Rule 10b5-1 trading plan that the director adopted on December 16, 2025. The plan was put in place to cover estimated tax liabilities associated with the vesting of restricted stock units.
Market movement since the trades shows the stock trading higher, reaching $24.38, although the share price remains down 34% year-to-date. An InvestingPro note cited in company commentary points to elevated volatility, with the stock exhibiting a beta of 3.99.
These insider sales come amid a backdrop of mixed company results and operational progress. Pelthos reported a material earnings miss for the fourth quarter of 2025, posting earnings per share of -6.87, well below the forecasted -0.54. At the same time, the company recorded sequential revenue growth of 28%, with fourth-quarter revenue of $9.1 million.
On the product and development front, Pelthos announced that the first patient has been dosed in a Phase 1b/2a clinical trial for CT2000, an investigational eye pain treatment. The trial is being carried out by the Australian subsidiary of Channel Pharmaceutical Corporation, a Pelthos subsidiary.
Analyst coverage has shown modest revision following Pelthos' year-end results and product launch progress. Oppenheimer increased its price target on the stock to $62 from $60 and maintained an Outperform rating. The firm cited year-end financials and the rollout of ZELSUVMI, which produced net product revenue of $16.2 million in 2025.
InvestingPro analysis included with the filings indicates that the stock currently appears overvalued relative to its Fair Value estimate. The company and the market are therefore displaying a combination of operational advancement and valuation questions as reflected in the recent insider activity and analyst commentary.
All details on the share counts, trade prices, plan adoption date, post-sale holdings, quarter results, revenue, clinical trial milestone, beta, and analyst price target are reported as disclosed in company filings and related notices.